Companies · ALGN
Align Technology
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 31, 2026
Align appoints iRhythm CEO Blackford to board; Saia retires after 13 years
Align Technology expanded its board to 11 directors by appointing Quentin Blackford, the current President and CEO of iRhythm Technologies, effective immediately. Blackford brings operational experience from Dexcom (COO) and capital-intensive medtech (NuVasive, Zimmer Holdings), strengthening board expertise in digital health and global operations at a time when Align is scaling its digital dentistry platform. Andrea Saia, a 13-year board member, will resign September 23, 2026, returning the board to ten directors.
Tone: neutralRevenue
$4B
ALGN 10-K · FY 2025
Employees
20,290
Revenue FY2024
$4B
Headquarters
Tempe, AZ
Profile
ALGN 10-K Item 1 · Feb 27, 2026Align Technology is a global medical device company that designs, manufactures, and markets the Invisalign clear aligner system, iTero intraoral scanners, and exocad CAD/CAM software for orthodontists, general dental practitioners, and dental laboratories. The company operates through two segments: Clear Aligner (approximately 80% of net revenues) and Imaging Systems and CAD/CAM Services. Its integrated Align Digital Platform connects patients, doctors, and labs across the full orthodontic and restorative treatment workflow.
Read filing description ↓ Collapse description ↑
Align Technology, Inc. is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign clear aligners for the treatment of malocclusions, or the misalignment of teeth, by orthodontists and general dental practitioners ('GPs'), Vivera retainers for retention, iTero intraoral scanners and services for dentistry, and exocad computer-aided design and computer-aided manufacturing ('CAD/CAM') software for dental laboratories and dental practitioners. Our vision and strategy is to revolutionize orthodontic and restorative dentistry through digital treatment planning and implementation using the Align Digital Platform, an integrated suite of proprietary technologies and services designed to deliver a seamless, end-to-end solution for patients, consumers, orthodontists, GPs and lab partners. We strive to achieve our vision and strategy through key objectives made possible with the proprietary technologies and services of the Align Digital Platform to establish: clear aligners as the principal solution for the treatment of malocclusions with the Invisalign System as the treatment solution of choice by orthodontists, GPs and patients globally, our iTero intraoral scanners as the preferred scanning technology for digital dental scans and our exocad CAD/CAM software as the dental restorative solution of choice for dental labs. We have two operating segments: (1) Clear Aligner and (2) Imaging Systems and CAD/CAM Services ('Systems and Services'). For the year ended December 31, 2025, Clear Aligner net revenues represented approximately 80% of worldwide net revenues, while Systems and Services net revenues represented the remaining 20%. We sell the majority of our products and services directly through a dedicated and specialized sales force to our customers: orthodontists, GPs, including prosthodontists, periodontists, oral surgeons and dental laboratories. To date, over 22 million people worldwide have been treated with the Invisalign System.
Primary products
- Invisalign clear aligners
- Vivera retainers
- iTero intraoral scanners
- exocad CAD/CAM software
- ClinCheck treatment planning software
- Invisalign Palatal Expander System
Business segments
End markets
Geographies
“We believe we are well positioned to compete in the markets we target. We have thousands of dedicated, highly skilled sales force employees who are focused on key portions of our target markets that allow us to uniquely address customer needs and thereby enhance the customer experience.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Net revenues increased modestly from approximately $3.999 billion in fiscal 2024 to approximately $4.035 billion in fiscal 2025, reflecting continued but decelerating growth against a backdrop of macroeconomic headwinds and currency pressures.
The rest of ALGN is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.